Nab-paclitaxel combinations for pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a chemotherapy drug (nab-paclitaxel) combined with other treatments for people with pancreatic cancer. The goal is to see if this combination helps control the cancer or prevents it from coming back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with pancreatic cancer that is either not removable by surgery, has spread, is at high risk of coming back, or was recently removed.
- You have not received chemotherapy for advanced disease, or if you did, it was more than 6 months ago.
- You are able to do daily activities with little or no help (ECOG score 0 or 1).
- Your vital organs such as bone marrow, liver, and kidneys are working well enough (checked by blood tests).
- You do not have certain other serious health problems, like uncontrolled heart disease, infections, or other cancers in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a chemotherapy combination (albumin-bound paclitaxel and gemcitabine) as first treatment for pancreatic cancer that cannot be removed by surgery. It aims to improve outcomes by testing how well this treatment works in people with locally advanced or metastatic disease.
This trial tests a combination of three chemotherapy drugs (irinotecan liposome, albumin-bound paclitaxel, and gemcitabine) as a first treatment for pancreatic cancer that hasn't spread. It aims to see if the combination can shrink tumors and improve survival with manageable side effects.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
This trial tests a combination of three drugs—anlotinib, benmelstobart, and chemotherapy—as a first treatment for pancreatic cancer that has spread. The goal is to see if this combo can shrink tumors or slow the cancer's growth better than current options.
This trial tests whether giving extra diabetes medication along with standard chemotherapy can help control blood sugar and improve outcomes in people with pancreatic cancer that has spread. It may help you manage diabetes better during treatment.
This trial tests a combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery for pancreatic cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.